
Please try another search
Precision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing therapies for gene edits, including gene insertion, excision, and elimination in the United States. The company offers ARCUS, a genome editing platform for DNA genome insertion, removal, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits, as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; and PBGENE-3243 for the treatment of m.3243 associated mitochondrial myopathy. In addition, the company develops PBGENE-NVS (insertion) for sickle cell and beta thalassemia diseases; PBGENE-DMD (excision) for duchenne muscular dystrophy; PBGENE-LIVER (insertion), a liver directed target; PBGENE-CNS (excision), a central nervous system directed target; and iECURE-OTC (insertion) for ornithine transcarbamylase deficiency. It has collaboration agreements with Novartis Pharma AG to discover and develop in vivo gene editing products; TG Cell Therapy, Inc. to develop, manufacture, and commercialize azer-cel for autoimmune diseases and other indications outside of cancer; and iECURE, Inc. to develop ARCUS-based gene-insertion therapies. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.
Name | Age | Since | Title |
---|---|---|---|
Derek Jantz | 46 | 2006 | Co-Founder & Chief Science Advisor |
Raymond F. Schinazi | 75 | 2019 | Member of Scientific Advisory Board |
Cameron J. Turtle | - | 2019 | Member of Scientific Advisory Board |
Melinda Brown | 69 | 2022 | Independent Director |
Shari Lisa Pire | 60 | 2021 | Independent Director |
Samuel E. Broder | 80 | 2018 | Member of Scientific Advisory Board |
Michael Amoroso | 47 | 2021 | President, CEO & Director |
Alan F. List | 70 | 2021 | Clinical Consultant & Member of Scientific Advisory Board |
Jordan Feld | - | 2024 | Member of Scientific Advisory Board |
Kenneth C. Anderson | 74 | 2019 | Member of Scientific Advisory Board |
Stanley R. Frankel | 66 | 2021 | Independent Director |
Geno J. Germano | 64 | 2020 | Independent Director |
Mark Sulkowski | - | 2024 | Member of Advisory Board |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review